Trinity Biotech

Trinity Biotech Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Trinity Biotech (TRIB) as of Oct 16, 2026 is 15.86 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 13.18 % — a change of 20.32% (higher).

Cash Conversion

15.86 %

YoY

20.32%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Trinity Biotech is 2025 15.86 % . Cash Conversion Rate (OCF/Net Income) of Trinity Biotech was 2024 13.18 % . It decreases by 20.32% higher compared to the previous year.

The Trinity Biotech Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
290.17 USD
Jan 1, 2019
-134.63 USD
Jan 1, 2020
-371.87 USD
Jan 1, 2021
1,512.91 USD
Jan 1, 2022
2.25 USD
Jan 1, 2023
48.12 USD
Jan 1, 2024
13.18 USD
Jan 1, 2025
15.86 USD
The Trinity Biotech Cash Conversion history
YEARCash ConversionYoY
15.86 %+20.32%
13.18 %-72.60%
48.12 %+2,042.17%
2.25 %-99.85%
1,512.91 %-506.84%
-371.87 %+176.22%
-134.63 %-146.40%
290.17 %-1,064.75%
-30.08 %+119.78%
-13.69 %-124.18%
56.59 %-38.16%
91.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Cash Conversion Rate (OCF/Net Income) of Trinity Biotech is 15.86 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Trinity Biotech changed from 13.18 % to 15.86 %, representing a 20.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Trinity Biotech

All Key Metrics — Trinity Biotech